Press Releases

Date Title and Summary View
Toggle Summary Revance Therapeutics Added to NASDAQ Biotechnology Index
NEWARK, Calif. , Dec. 18, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today that it has been selected for addition to the NASDAQ
View HTML
Toggle Summary Revance Therapeutics, Inc. Announces Participation in 26th Annual Piper Jaffray Healthcare Conference
NEWARK, Calif. , Nov. 20, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that its management is scheduled to participate in the 26 th Annual Piper
View HTML
Toggle Summary Revance Therapeutics Releases Third Quarter 2014 Results
- Confirmation of Plans to Initiate Phase 2 Active Comparator Study for RT002 in 2014 - - Updated Full Year 2014 Financial Guidance - NEWARK, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use
View HTML
Toggle Summary Revance Therapeutics, Inc. Announces Participation in Credit Suisse 2014 Healthcare Conference
NEWARK, Calif. , Nov. 4, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that its management is scheduled to participate in the Credit Suisse 2014
View HTML
Toggle Summary Revance Therapeutics to Release Third Quarter 2014 Financial Results and Host Conference Call on Wednesday, November 12, 2014
NEWARK, Calif., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today that the Company will release third quarter 2014 financial results on
View HTML
Toggle Summary Revance Therapeutics Provides Update on RT001 Clinical Program for the Lead Indication for Crow's Feet Lines
NEWARK, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company has initiated a study to confirm this quarter the successful
View HTML
Toggle Summary Revance Therapeutics Announces the Appointment of Azita Nejad as Vice President of Quality
Inducement Grants Awarded Under NASDAQ Listing Rule 5635(c)(4)
View HTML
Toggle Summary Revance Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWARK, Calif., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the Compensation Committee of its Board of Directors granted an
View HTML
Toggle Summary Revance Therapeutics Appoints Industry Veteran Arthur P. Bertolino, M.D., Ph.D., M.B.A. as Chief Medical Officer
NEWARK, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that it has strengthened its leadership team with the appointment of Arthur
View HTML
Toggle Summary Revance Therapeutics Releases Second Quarter 2014 Financial Results
Reiterates Full-Year Financial Guidance
View HTML
Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools